CPRX vs PVLA
CPRX: Catalyst Pharma commercializes rare disease therapies with a focus on neuromuscular and neuromuscular-inflammation disorders, generating strong cash flow from established and newly approved products. PVLA: A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris Pharmaceuticals and Legacy Palvella.
Side-by-side fundamentals
| Metric | CPRX | PVLA | Edge |
|---|---|---|---|
| Price as of 2026-07-21 close | $31.49 | $142.18 | |
| Market cap as of 2026-07-23 | $3.9B | $2.0B | |
| P/E as of 2026-07-23 | 17.42 | n/a | |
| PEG as of 2026-07-23 | 1.44 | n/a | |
| Net margin as of 2026-07-23 | +37.1% | -39.7% | CPRX higher |
| Gross margin as of 2026-07-23 | +86.0% | n/a | |
| Operating margin as of 2026-07-23 | +44.8% | -47.8% | CPRX higher |
| ROE as of 2026-07-23 | +23.6% | -56.9% | CPRX higher |
| ROA as of 2026-07-23 | +20.7% | -42.5% | CPRX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.09 | CPRX lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.7% | -97.2% | CPRX higher |
| Revenue CAGR (3y) SEC XBRL | +40.1% | +13.4% | CPRX higher |
| Beta as of 2026-07-23 | 0.78 | -0.20 | |
| 1-year return as of 2026-07-21 close | +45.7% | +294.9% | PVLA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.